Activation of AKT kinases in cancer: implications for therapeutic targeting - PubMed (original) (raw)
Review
Activation of AKT kinases in cancer: implications for therapeutic targeting
Alfonso Bellacosa et al. Adv Cancer Res. 2005.
Abstract
The AKT1, AKT2, and AKT3 kinases have emerged as critical mediators of signal transduction pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase. An ever-increasing list of AKT substrates has precisely defined the multiple functions of this kinase family in normal physiology and disease states. Cellular processes regulated by AKT include cell proliferation and survival, cell size and response to nutrient availability, intermediary metabolism, angiogenesis, and tissue invasion. All these processes represent hallmarks of cancer, and a burgeoning literature has defined the importance of AKT alterations in human cancer and experimental models of tumorigenesis, continuing the legacy represented by the original identification of v-Akt as the transforming oncogene of a murine retrovirus. Many oncoproteins and tumor suppressors intersect in the AKT pathway, finely regulating cellular functions at the interface of signal transduction and classical metabolic regulation. This careful balance is altered in human cancer by a variety of activating and inactivating mechanisms that target both AKT and interrelated proteins. Reprogramming of this altered circuitry by pharmacologic modulation of the AKT pathway represents a powerful strategy for rational cancer therapy. In this review, we summarize a large body of data, from many types of cancer, indicating that AKT activation is one of the most common molecular alterations in human malignancy. We also review mechanisms of activation of AKT kinases, examples of therapeutic modulation of the AKT pathway in animal models, and the current status of efforts to target molecular components of the AKT pathway for cancer therapy and, possibly, cancer prevention.
Similar articles
- Functional and therapeutic significance of Akt deregulation in malignant melanoma.
Robertson GP. Robertson GP. Cancer Metastasis Rev. 2005 Jun;24(2):273-85. doi: 10.1007/s10555-005-1577-9. Cancer Metastasis Rev. 2005. PMID: 15986137 Review. - Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
Menendez JA, Colomer R, Lupu R. Menendez JA, et al. Med Hypotheses. 2005;64(2):342-9. doi: 10.1016/j.mehy.2004.07.022. Med Hypotheses. 2005. PMID: 15607569 - AKT signaling in normal and malignant cells.
Testa JR, Tsichlis PN. Testa JR, et al. Oncogene. 2005 Nov 14;24(50):7391-3. doi: 10.1038/sj.onc.1209100. Oncogene. 2005. PMID: 16288285 - PI3K/Akt signalling pathway and cancer.
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. Fresno Vara JA, et al. Cancer Treat Rev. 2004 Apr;30(2):193-204. doi: 10.1016/j.ctrv.2003.07.007. Cancer Treat Rev. 2004. PMID: 15023437 Review. - Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Yang L, et al. Cancer Res. 2004 Jul 1;64(13):4394-9. doi: 10.1158/0008-5472.CAN-04-0343. Cancer Res. 2004. PMID: 15231645
Cited by
- Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors.
Poustforoosh A. Poustforoosh A. Mol Biotechnol. 2024 Oct 27. doi: 10.1007/s12033-024-01307-2. Online ahead of print. Mol Biotechnol. 2024. PMID: 39463205 - AKT and PERP Show Higher Expression in Precancerous than in Malignant Skin Neoplasms: Profiling in an Animal Model of Sequential Skin Carcinogenesis.
Vairaktari E, Schramm A, Vairaktari G, Derka S, Wilde F, Sakkas A, Yapijakis C, Kouri M, Balakas A, Lazaris A, Ebeling M, Vassiliou S. Vairaktari E, et al. J Pers Med. 2024 Jul 25;14(8):790. doi: 10.3390/jpm14080790. J Pers Med. 2024. PMID: 39201982 Free PMC article. - Treatment-related adverse events in patients with advanced breast cancer receiving adjuvant AKT inhibitors: a meta-analysis of randomized controlled trials.
de Moraes FCA, Sano VKT, Pereira CRM, de Laia EA, Stecca C, Magalhães MCF, Burbano RMR. de Moraes FCA, et al. Eur J Clin Pharmacol. 2024 Sep;80(9):1373-1385. doi: 10.1007/s00228-024-03713-6. Epub 2024 Jun 18. Eur J Clin Pharmacol. 2024. PMID: 38888626 - An in silico approach to identify novel and potential Akt1 (protein kinase B-alpha) inhibitors as anticancer drugs.
Etikyala U, Reddyrajula R, Vani T, Kuchana V, Dalimba U, Manga V. Etikyala U, et al. Mol Divers. 2024 May 26. doi: 10.1007/s11030-024-10887-9. Online ahead of print. Mol Divers. 2024. PMID: 38796797 - IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis.
Yang K, Hu Y, Feng Y, Li K, Zhu Z, Liu S, Lin Y, Yu B. Yang K, et al. J Exp Clin Cancer Res. 2024 Feb 12;43(1):46. doi: 10.1186/s13046-024-02970-8. J Exp Clin Cancer Res. 2024. PMID: 38342894 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA06927/CA/NCI NIH HHS/United States
- CA097097/CA/NCI NIH HHS/United States
- CA105008/CA/NCI NIH HHS/United States
- CA77429/CA/NCI NIH HHS/United States
- CA83638/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous